Short Interest in INVO Bioscience, Inc. (NASDAQ:INVO) Grows By 144.7%

INVO Bioscience, Inc. (NASDAQ:INVO) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 75,600 shares, a growth of 144.7% from the May 31st total of 30,900 shares. Based on an average daily trading volume, of 3,800,000 shares, the short-interest ratio is currently 0.0 days. Currently, 2.0% of the shares of the stock are sold short.

Institutional Trading of INVO Bioscience

An institutional investor recently bought a new position in INVO Bioscience stock. Sabby Management LLC acquired a new position in shares of INVO Bioscience, Inc. (NASDAQ:INVO) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 231,023 shares of the company’s stock, valued at approximately $183,000. INVO Bioscience makes up 0.1% of Sabby Management LLC’s holdings, making the stock its 29th biggest holding. Sabby Management LLC owned about 9.43% of INVO Bioscience at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors.

INVO Bioscience Trading Down 3.3 %

INVO traded down $0.03 during midday trading on Friday, hitting $0.84. 19,222 shares of the company traded hands, compared to its average volume of 124,025. The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.03. The company has a debt-to-equity ratio of 2.94, a quick ratio of 0.16 and a current ratio of 0.19. INVO Bioscience has a 52-week low of $0.50 and a 52-week high of $7.20.

INVO Bioscience (NASDAQ:INVO) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $1.58 million for the quarter.

About INVO Bioscience

INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.